ArticleACS synthetic biology2022
Discovery and Heterologous Expression of Microginins from
Article in ACS synthetic biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A guide to Direct Pathway Cloning (DiPaC) for natural product discovery.Essays in biochemistry · 2026Review
- Heterologous expression of NRPS and PKS pathways in Escherichia coli: from bottlenecks to biosynthetic platforms.Essays in biochemistry · 2026Review
- The Maculalactone Biosynthetic Gene Cluster, a Cryptic Furanolide Pathway Revealed inACS synthetic biology · 2026Article
- Secondary metabolism ofApplied and environmental microbiology · 2026Review
- Phosphorylation of peptides by a kinase domain in cyanobactin pathways.Nature communications · 2025Article
- Recent advances in microbially derived chlorinated antiparasitic compounds.Molecular diversity · 2025Review
- The Complete Genomes ofMicroorganisms · 2025Article
- Chemodiversity and Biotechnological Potential of Microginins.International journal of molecular sciences · 2025Review
- Cyanobacterial Peptides in Anticancer Therapy: A Comprehensive Review of Mechanisms, Clinical Advances, and Biotechnological Innovation.Marine drugs · 2025Review
- Heterologous Expression of a Cryptic BGC fromACS synthetic biology · 2025Article
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Expanding the Diversity of the Cyanobacterial Dialkylresorcinol Bartoloside Family.Journal of natural products · 2024Article
- Genome Mining ofMicroorganisms · 2024Article
- Heterologous expression facilitates the discovery and characterization of marine microbial natural products.Engineering microbiology · 2024Review
- Bacillamide D produced by Bacillus cereus from the mouse intestinal bacterial collection (miBC) is a potent cytotoxin in vitro.Communications biology · 2024Article
- Natural Products That Contain Higher Homologated Amino Acids.Chembiochem : a European journal of chemical biology · 2024Review
- More than just an eagle killer: The freshwater cyanobacteriumProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Expression ofApplied and environmental microbiology · 2023Article
- Incorporation and modification of fatty acids in cyanobacterial natural products biosynthesis.Chemical communications (Cambridge, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microginins are a large family of cyanobacterial lipopeptide protease inhibitors. A hybrid polyketide synthase/non-ribosomal peptide synthetase biosynthetic gene cluster (BGC) found in several microginin-producing strains─
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.